Roger E G Schutgens

List of Publications by Year in Descending Order

216 papers	3,441 citations	29 h-index	51 g-index
233 ext. papers	4,285 ext. citations	5.6 avg, IF	5.42 L-index

#	Paper	IF	Citations
216	Checklist Individual Strength to measure severe fatigue in immune thrombocytopenia.. *British Journal of Haematology*, **2022**,	4.5	
215	Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study).. *TH Open*, **2022**, 6, e60-e69	2.7	
214	Relapse of immune thrombocytopenia after COVID-19 vaccination. *European Journal of Haematology*, **2022**, 108, 84-85	3.8	1
213	Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia.. *HemaSphere*, **2022**, 6, e694	0.3	
212	Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study.. *American Journal of Hematology*, **2022**,	7.1	1
211	Prevalence, burden and treatment effects of vaginal bleeding in women with (suspected) congenital platelet disorders throughout life: a cross-sectional study. *British Journal of Haematology*, **2021**,	4.5	2
210	Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. *Blood Advances*, **2021**,	7.8	1
209	Identification of Biomarkers That Are Associated with Clinical Complications of Hemoglobin SC Disease and Sickle Cell Anemia. *Blood*, **2021**, 138, 962-962	2.2	0
208	Recombinant Porcine Factor VIII in Patients with Congenital Hemophilia a with Inhibitors Undergoing Surgery: Phase 3, Multicenter, Single Arm, Open-Label Study. *Blood*, **2021**, 138, 2109-2109	2.2	
207	Safety and Efficacy of Mitapivat (AG-348), an Oral Activator of Pyruvate Kinase R, in Subjects with Sickle Cell Disease: A Phase 2, Open-Label Study (ESTIMATE). *Blood*, **2021**, 138, 2047-2047	2.2	1
206	Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. *Lancet Neurology, The*, **2021**, 20, 907-916	24.1	9
205	Challenges in biomarker research in haemophilic arthropathy. *Haemophilia*, **2021**, 27, e547-e548	3.3	0
204	Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A. *HemaSphere*, **2021**, 5, e557	0.3	
203	On-demand treatment with the iron chelator deferasirox is ineffective in preventing blood-induced joint damage in haemophilic mice. *Haemophilia*, **2021**, 27, 648-656	3.3	1
202	Adherence to prophylaxis and its association with activation of self-management and treatment satisfaction. *Haemophilia*, **2021**, 27, 581-590	3.3	2
201	A simplified decision rule to rule out deep vein thrombosis using clinical assessment and D-dimer. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 1752-1758	15.4	1
200	Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy. *Blood*, **2021**, 137, 2997-3001	2.2	6

199	Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen. *Thrombosis and Haemostasis*, **2021**,	7	1
198	Alternatives for Vitamin K Antagonists as Thromboprophylaxis for Mechanical Heart Valves and Mechanical Circulatory Support Devices: A Systematic Review. *Seminars in Thrombosis and Hemostasis*, **2021**, 47, 724-734	5.3	1
197	Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 1896-1906	15.4	4
196	COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. *Lancet Haematology,the*, **2021**, 8, e524-e533	14.6	77
195	Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. *Lancet Haematology,the*, **2021**, 8, e492-e502	14.6	2
194	Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients. *Blood Reviews*, **2021**, 47, 100774	11.1	3
193	Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study. *American Journal of Hematology*, **2021**, 96, 51-59	7.1	6
192	Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. *British Journal of Clinical Pharmacology*, **2021**, 87, 2602-2613	3.8	4
191	Obstetrical bleeding in women with MYH9-related disease-A systematic review. *Haemophilia*, **2021**, 27, e278-e283	3.3	2
190	Biochemical marker research in hemophilic arthropathy: A systematic review. *Blood Reviews*, **2021**, 47, 100781	11.1	1
189	Oxygen gradient ektacytometry-derived biomarkers are associated with vaso-occlusive crises and correlate with treatment response in sickle cell disease. *American Journal of Hematology*, **2021**, 96, E29-E32	7.1	9
188	The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
187	Anti-β2-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 1018-1028	15.4	10
186	Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. *EClinicalMedicine*, **2021**, 32, 100726	11.3	10
185	Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review. *Clinical Pharmacokinetics*, **2021**, 60, 1395-1406	6.2	2
184	Platelet count and indices as postpartum hemorrhage risk factors: a retrospective cohort study. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2873-2883	15.4	0
183	Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review. *Blood Reviews*, **2021**, 49, 100826	11.1	3
182	Shortening the Haemophilia Activities List (HAL) from 42 items to 18 items. *Haemophilia*, **2021**, 27, 1062-1070	3.9	0

181	Coordinating physiotherapy care for persons with haemophilia. *Haemophilia*, **2021**, 27, 1051-1061	3.3	0
180	Glanzmann thrombasthenia complicated by frequent myeloproliferative neoplasm-related thromboembolism: thrombosis occurring regardless of IIbIII integrin deficiency. *Clinical Case Reports (discontinued)*, **2021**, 9, e04757	0.7	
179	Dentoalveolar Procedures in Immune Thrombocytopenia; Systematic Review and an Institutional Guideline. *TH Open*, **2021**, 5, e489-e502	2.7	1
178	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients. *Thrombosis and Haemostasis*, **2020**, 120, 1056-1065	7	2
177	Diagnosing deep vein thrombosis in cancer patients with suspected symptoms: An individual participant data meta-analysis. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2245-2252	15.4	4
176	Bleeding phenotype and diagnostic characterization of patients with congenital platelet defects. *American Journal of Hematology*, **2020**, 95, 1142	7.1	3
175	Proteoglycan synthesis rate as a novel method to measure blood-induced cartilage degeneration in non-haemophilic and haemophilic rats. *Haemophilia*, **2020**, 26, e88-e96	3.3	4
174	Movement behaviour patterns in adults with haemophilia. *Therapeutic Advances in Hematology*, **2020**, 11, 2040620719896959	5.7	5
173	Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial. *PLoS Medicine*, **2020**, 17, e1003142	11.6	6
172	The Perspectives of Adolescents and Young Adults on Adherence to Prophylaxis in Hemophilia: A Qualitative Study. *Patient Preference and Adherence*, **2020**, 14, 163-171	2.4	5
171	Congenital platelet disorders and health status-related quality of life. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 100-105	5.1	3
170	AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years. *Blood*, **2020**, 136, 26-26	2.2	5
169	Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc. *TH Open*, **2020**, 4, e362-e364	2.7	1
168	A Blended Physiotherapy Intervention for Persons With Hemophilic Arthropathy: Development Study. *Journal of Medical Internet Research*, **2020**, 22, e16631	7.6	5
167	The limitation of genetic testing in diagnosing patients suspected for congenital platelet defects. *American Journal of Hematology*, **2020**, 95, E26-E28	7.1	3
166	Maternal and neonatal bleeding complications in relation to peripartum management in women with Von Willebrand disease: A systematic review. *Blood Reviews*, **2020**, 39, 100633	11.1	15
165	One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P /Humate P treatment in von Willebrand disease patients. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 295-305	15.4	4
164	Flow cytometric mepacrine fluorescence can be used for the exclusion of platelet dense granule deficiency. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 706-713	15.4	10

163	Clinical pre-test probability adjusted versus age-adjusted D-dimer interpretation strategy for DVT diagnosis: A diagnostic individual patient data meta-analysis. *Journal of Thrombosis and Haemostasis* , **2020**, 18, 669-675	15.4	8
162	Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study. *Blood Advances*, **2020**, 4, 5025-5034	7.8	6
161	A Pathophysiological Perspective on the SARS-CoV-2 Coagulopathy. *HemaSphere*, **2020**, 4, e457	0.3	2
160	A feasibility study on two tailored interventions to improve adherence in adults with haemophilia. *Pilot and Feasibility Studies*, **2020**, 6, 189	1.9	4
159	Abnormal coagulation parameters are a common non-neuromuscular feature in patients with spinal muscular atrophy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 212-214	5.5	7
158	Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial **2020**, 17, e1003142		
157	Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial **2020**, 17, e1003142		
156	Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial **2020**, 17, e1003142		
155	Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial **2020**, 17, e1003142		
154	An update on the Œdanger theoryŒ on inhibitor development in hemophilia A. *Expert Review of Hematology*, **2019**, 12, 335-344	2.8	5
153	The Paediatric Haemophilia Activities List (pedHAL) in routine assessment: changes over time, child-parent agreement and informative domains. *Haemophilia*, **2019**, 25, 953-959	3.3	4
152	Catheter Ablation for Atrial Fibrillation in Patients with Hemophilia or von Willebrand Disease. *TH Open*, **2019**, 3, e335-e339	2.7	2
151	Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B. *Blood*, **2019**, 134, 2059-2059	2.2	28
150	Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients. *American Journal of Hematology*, **2019**, 94, 575-584	7.1	24
149	Reliability and Feasibility of the Self-Administered ISTH-Bleeding Assessment Tool. *TH Open*, **2019**, 3, e350-e355	2.7	4
148	Organ involvement occurs in all forms of hereditary haemolytic anaemia. *British Journal of Haematology*, **2019**, 185, 602-605	4.5	1
147	The prevalence and burden of hand and wrist bleeds in von Willebrand disease. *Haemophilia*, **2019**, 25, e35-e38	3.3	4
146	Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. *The Cochrane Library*, **2019** , 4, CD011385	5.2	5

145	Review of immune tolerance induction in hemophilia A. *Blood Reviews*, **2018**, 32, 326-338	11.1	30
144	Movement behaviour in adults with haemophilia compared to healthy adults. *Haemophilia*, **2018**, 24, 445-451	3.3	10
143	Validation of flow cytometric analysis of platelet function in patients with a suspected platelet function defect. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 689-698	15.4	26
142	Should vitamin K be supplemented instead of antagonised in patients with idiopathic pulmonary fibrosis?. *Expert Review of Respiratory Medicine*, **2018**, 12, 169-175	3.8	3
141	Toward Flow Cytometry Based Platelet Function Diagnostics. *Seminars in Thrombosis and Hemostasis*, **2018**, 44, 197-205	5.3	19
140	The combination of urinary CTX-II and serum CS-846: Promising biochemical markers to predict radiographic progression of haemophilic arthropathy-An exploratory study. *Haemophilia*, **2018**, 24, e278-e280	3.3	3
139	Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A. *Haemophilia*, **2018**, 24, e280-e283	3.3	4
138	Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy. *Blood*, **2018**, 132, 3476-3476	2.2	3
137	The Oxygenscan: A Rapid and Reproducible Test to Determine Patient-Specific, Clinically Relevant Biomarkers of Disease Severity in Sickle Cell Anemia. *Blood*, **2018**, 132, 2360-2360	2.2	1
136	Phosphatidylserine-Exposing Extracellular Vesicles after Splenectomy Are Associated with Increased D-Dimers and Fibrin Generation in Hereditary Hemolytic Anemia. *Blood*, **2018**, 132, 630-630	2.2	
135	Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments. *Haemophilia*, **2018**, 24, e33-e49	3.3	13
134	Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. *Blood*, **2018**, 131, 1022-1031	2.2	161
133	Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis. *Thrombosis and Haemostasis*, **2018**, 118, 1690-1700	7	6
132	Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 2196-2207	15.4	6
131	Familial macrothrombocytopenia due to a double mutation in cis in the alpha-actinin 1 gene (ACTN1), previously considered to be chronic immune thrombocytopenic purpura. *Pediatric Blood and Cancer*, **2018**, 65, e27418	3	2
130	Diagnostische vertraging bij longembolie. *Huisarts En Wetenschap*, **2018**, 61, 29-32	0.1	
129	No Relation between Platelet Activity and Haemophilia B Phenotype. *Thrombosis and Haemostasis*, **2018**, 118, 1481-1483	7	
128	Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions. *The Cochrane Library*, **2018**, 7, CD012293	5.2	8

127	Plasma fibrinogen level as a potential predictor of hemorrhagic complications after catheter-directed thrombolysis for peripheral arterial occlusions. *Journal of Vascular Surgery*, **2017**, 65, 1519-1527.e26	3.5	16
126	Clinical characteristics associated with diagnostic delay of pulmonary embolism in primary care: a retrospective observational study. *BMJ Open*, **2017**, 7, e012789	3	16
125	Screening for hemosiderosis in patients receiving multiple red blood cell transfusions. *European Journal of Haematology*, **2017**, 98, 478-484	3.8	3
124	Differential effects of bleeds on the development of arthropathy - basic and applied issues. *Haemophilia*, **2017**, 23, 521-527	3.3	22
123	Pathophysiology of hemophilic arthropathy and potential targets for therapy. *Pharmacological Research*, **2017**, 115, 192-199	10.2	54
122	Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. *Haematologica*, **2017**, 102, 1486-1493	6.6	14
121	Comparing findings of routine Haemophilia Joint Health Score and Haemophlia Early Arthropathy Detection with UltraSound assessments in adults with haemophilia. *Haemophilia*, **2017**, 23, e141-e143	3.3	21
120	Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 868-875	15.4	4
119	Hemophilic Arthropathy **2017**, 2007-2017		2
118	A fusion protein of interleukin-4 and interleukin-10 protects against blood-induced cartilage damage in vitro and in vivo. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 1788-1798	15.4	15
117	Minimal factor XIII activity level to prevent major spontaneous bleeds. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 1728-1736	15.4	22
116	Pathophysiological Mechanisms of Endogenous FVIII Release following Strenuous Exercise in Non-severe Haemophilia: A Review. *Thrombosis and Haemostasis*, **2017**, 117, 2237-2242	7	4
115	Joint assessment in von Willebrand disease. Validation of the Haemophilia Joint Health score and Haemophilia Activities List. *Thrombosis and Haemostasis*, **2017**, 117, 1465-1470	7	7
114	Management of cardiovascular disease in aging persons with haemophilia. *Hamostaseologie*, **2017**, 37, 196-201	1.9	6
113	Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia. *Haemophilia*, **2016**, 22, 852-858	3.3	11
112	New concepts for anticoagulant therapy in persons with hemophilia. *Blood*, **2016**, 128, 2471-2474	2.2	25
111	The association of haemophilic arthropathy with Health-Related Quality of Life: a post hoc analysis. *Haemophilia*, **2016**, 22, 833-840	3.3	14
110	First preclinical support for the Œdanger theory On inhibitor development. *Haemophilia*, **2016**, 22, 654-6	3.3	1

109	Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing oral or dental procedures. *The Cochrane Library*, **2016**,	5.2	1
108	Joint surgery in von Willebrand disease: a multicentre cross-sectional study. *Haemophilia*, **2016**, 22, 256-262	3.3	2
107	A patient with severe haemophilia A and multiple arterial thromboses caused by large vessel vasculitis: a case report. *Haemophilia*, **2016**, 22, e39-42	3.3	
106	Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B. *Blood*, **2016**, 128, 2314-2314	2.2	5
105	Multiple joint procedures in haemophilia: benefit of self-reported activities. *The Journal of Haemophilia Practice*, **2016**, 3, 55-61	0.2	
104	Clinical Joint Outcome after Joint Bleeds in Patients with Von Willebrand Disease Is Comparable to Moderate and Severe Hemophilia A Despite Fewer Joint Bleeds. *Blood*, **2016**, 128, 3789-3789	2.2	1
103	Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study). *Blood*, **2016**, 128, 207-207	2.2	
102	Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. *Thrombosis and Haemostasis*, **2016**, 115, 931-8	7	29
101	Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment. *Haemophilia*, **2016**, 22, e1-e10	3.3	19
100	FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. *Haemophilia*, **2016**, 22, e36-8	3.3	10
99	How do patients and professionals differentiate between intra-articular joint bleeds and acute flare-ups of arthropathy in patients with haemophilia?. *Haemophilia*, **2016**, 22, 368-73	3.3	6
98	Silencing of protease-activated receptors attenuates synovitis and cartilage damage following a joint bleed in haemophilic mice. *Haemophilia*, **2016**, 22, 152-9	3.3	4
97	The detrimental effects of iron on the joint: a comparison between haemochromatosis and haemophilia. *Journal of Clinical Pathology*, **2015**, 68, 592-600	3.9	24
96	Differentiating between signs of intra-articular joint bleeding and chronic arthropathy in haemophilia: a narrative review of the literature. *Haemophilia*, **2015**, 21, 289-96	3.3	28
95	Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. *Haemophilia*, **2015**, 21, e185-92	3.3	27
94	Core diameter of bone marrow aspiration devices influences cell density of bone marrow aspirate in patients with severe peripheral artery disease. *Cytotherapy*, **2015**, 17, 1807-12	4.8	1
93	Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine in vivo study. *Osteoarthritis and Cartilage*, **2015**, 23, 63-9	6.2	39
92	Partial pyruvate kinase deficiency aggravates the phenotypic expression of band 3 deficiency in a family with hereditary spherocytosis. *American Journal of Hematology*, **2015**, 90, E35-9	7.1	20

91	First report of inhibitory von Willebrand factor alloantibodies in type 2B von Willebrand disease. *British Journal of Haematology*, **2015**, 171, 424-7	4.5	9
90	IL-1β in contrast to TNFα is pivotal in blood-induced cartilage damage and is a potential target for therapy. *Blood*, **2015**, 126, 2239-46	2.2	46
89	Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. *Haemophilia*, **2015**, 21, 419-29	3.3	18
88	Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. *Trials*, **2015**, 16, 393	2.8	54
87	Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. *The Cochrane Library*, **2015** , CD011385	5.2	15
86	The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A. *Thrombosis and Haemostasis*, **2015**, 114, 639-44	7	20
85	Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A. *Haemophilia*, **2015**, 21, e19-25	3.3	10
84	Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. *Circulation*, **2015**, 131, 851-60	16.7	111
83	Renal Status and Hematuria in Older Patients with Hemophilia. *Blood*, **2015**, 126, 2290-2290	2.2	1
82	Antiplasmin, but not amiloride, prevents synovitis and cartilage damage following hemarthrosis in hemophilic mice. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 237-45	15.4	12
81	Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. *BMJ, The*, **2014**, 348, g1340	5.9	116
80	Hemarthrosis in hemophilic mice results in alterations in M1-M2 monocyte/macrophage polarization. *Thrombosis Research*, **2014**, 133, 390-5	8.2	26
79	Management of atrial fibrillation in people with haemophilia--a consensus view by the ADVANCE Working Group. *Haemophilia*, **2014**, 20, e417-20	3.3	10
78	Antifibrinolytic therapy for preventing oral bleeding in patients with a hemophilia or Von Willebrand disease undergoing oral or dental procedures **2014**,		4
77	Deferasirox limits cartilage damage following haemarthrosis in haemophilic mice. *Thrombosis and Haemostasis*, **2014**, 112, 1044-50	7	11
76	Platelet degranulation and glycoprotein IIbIIIa opening are not related to bleeding phenotype in severe haemophilia A patients. *Thrombosis and Haemostasis*, **2014**, 111, 1022-30	7	4
75	Uitsluiten van DVT met een klinische beslisregel. *Huisarts En Wetenschap*, **2014**, 57, 626-628	0.1	
74	Old Age Medicine and Hemophilia **2014**, 154-162		

73	Factor VIII concentrate infusion in patients with haemophilia results in decreased von Willebrand factor and ADAMTS-13 activity. *Haemophilia*, **2014**, 20, 92-8	3.3	8
72	Atrial fibrillation in patients with haemophilia: a cross-sectional evaluation in Europe. *Haemophilia*, **2014**, 20, 682-6	3.3	26
71	No Association Between Platelet Function and Hemophilia B Phenotype. *Blood*, **2014**, 124, 4994-4994	2.2	1
70	Interleukin-1 Is Essential for Blood-Induced Cartilage Damage In Vitro. *Blood*, **2014**, 124, 240-240	2.2	
69	Stimulation of naïve monocytes and PBMCs with coagulation proteases results in thrombin-mediated and PAR-1-dependent cytokine release and cell proliferation in PBMCs only. *Scandinavian Journal of Immunology*, **2013**, 77, 339-49	3.4	12
68	Anticoagulation therapy in haemophilia. Managing the unknown. *Hamostaseologie*, **2013**, 33, 299-304	1.9	10
67	Cardiac catheterization and intervention in haemophilia patients: prospective evaluation of the 2009 institutional guideline. *Haemophilia*, **2013**, 19, 370-7	3.3	20
66	Diagnostic possibilities of specific fibrin(ogen) degradation products in relation to venous thromboembolism. *Blood Coagulation and Fibrinolysis*, **2013**, 24, 297-304	1	2
65	Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients. *British Journal of Haematology*, **2013**, 162, 827-35	4.5	7
64	Obesity in haemophilia patients: effect on bleeding frequency, clotting factor concentrate usage, and haemostatic and fibrinolytic parameters. *Haemophilia*, **2013**, 19, 744-52	3.3	15
63	Identification and expression of iron regulators in human synovium: evidence for upregulation in haemophilic arthropathy compared to rheumatoid arthritis, osteoarthritis, and healthy controls. *Haemophilia*, **2013**, 19, e218-27	3.3	24
62	Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia - an assessment by the ADVANCE Working Group. *Haemophilia*, **2013**, 19, 833-40	3.3	34
61	Cataract surgery in haemophilia. *Haemophilia*, **2013**, 19, e371-2	3.3	1
60	Response to desmopressin in patients with mild hemophilia A caused by the F8 c.1910A>G, p.Asn637Ser mutation. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 2179-81	15.4	
59	Patient autoantibodies induce platelet destruction signals via raft-associated glycoprotein Ib and Fc RIIa in immune thrombocytopenia. *Haematologica*, **2013**, 98, e70-2	6.6	15
58	Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. *Thrombosis and Haemostasis*, **2013**, 109, 16-23	7	52
57	Haemarthrosis stimulates the synovial fibrinolytic system in haemophilic mice. *Thrombosis and Haemostasis*, **2013**, 110, 173-83	7	20
56	Comment on Stem-cell therapy for peripheral arterial occlusive disease *European Journal of Vascular and Endovascular Surgery*, **2012**, 43, 486; author reply 487	2.3	

55	History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia. *European Journal of Haematology*, **2012**, 89, 336-9	3.8	23
54	Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 799-804	9.4	44
53	Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients. *Thrombosis Research*, **2012**, 130, 157-62	8.2	40
52	Coagulation aggravates blood-induced joint damage in dogs. *Arthritis and Rheumatism*, **2012**, 64, 3231-9		8
51	Von Willebrand factor deficiency and atherosclerosis. *Blood Reviews*, **2012**, 26, 189-96	11.1	33
50	Persistent A-antigen after stem cell transplantation of blood group A patient with non-A donor. *American Journal of Hematology*, **2012**, 87, E118-9	7.1	2
49	Successful transfusion care for a patient with the Rhesus -D- phenotype and antibodies against Rh17 and two additional alloantibodies. *Annals of Hematology*, **2012**, 91, 963-4	3	4
48	Factor VIII deficiency does not protect against atherosclerosis. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 30-7	15.4	48
47	Risk of inhibitor development in mild haemophilia A increases with age. *Haemophilia*, **2012**, 18, 263-7	3.3	31
46	Does haemophilia protect against ischaemic cardiovascular disease?. *Haemophilia*, **2012**, 18, e35-6	3.3	2
45	Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. *Haematologica*, **2012**, 97, 1507-13	6.6	76
44	Increased prevalence of hypertension in haemophilia patients. *Thrombosis and Haemostasis*, **2012**, 108, 750-5	7	54
43	A cascade of thromboembolic processes in a patient with paroxysmal nocturnal haemoglobinuria terminated by treatment with eculizumab. *Thrombosis and Haemostasis*, **2011**, 106, 383-5	7	5
42	No firm association between N-terminal pro-brain natriuretic peptide and percentage of pulmonary vascular obstruction in patients with acute pulmonary embolism. *Thrombosis Research*, **2011**, 127, 547-50	8.2	3
41	Repeated NT-proBNP testing and risk for adverse outcome after acute pulmonary embolism. *Thrombosis and Haemostasis*, **2011**, 106, 1226-7	7	1
40	Patients with deep venous thrombosis and thrombophilia risk factors have a specific prolongation of the lag time in a chromogenic thrombin generation assay. *Blood Coagulation and Fibrinolysis*, **2011**, 22, 506-11	1	1
39	Clinical severity of haemophilia A: does the classification of the 1950s still stand?. *Haemophilia*, **2011**, 17, 849-53	3.3	156
38	Scuba diving by patients with haemophilia: a few notes of precaution. *Haemophilia*, **2011**, 17, e1007-8; author reply e1008-9	3.3	

37	A prognostic model for short term adverse events in normotensive patients with pulmonary embolism. *American Journal of Hematology*, **2011**, 86, 646-9	7.1	21
36	Up-regulation of platelet activation in hemophilia A. *Haematologica*, **2011**, 96, 888-95	6.6	25
35	A thrombin generation assay may reduce the need for compression ultrasonography for the exclusion of deep venous thrombosis in the elderly. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2011**, 71, 12-8	2	8
34	Role of glycoprotein Ibalpha mobility in platelet function. *Thrombosis and Haemostasis*, **2010**, 103, 1033-43	7	15
33	Out of hospital anticoagulant therapy in patients with acute pulmonary embolism is frequently practised but not perfect. *Thrombosis Research*, **2010**, 126, 481-5	8.2	7
32	Hemophilia and Medicine in Old Age **2010**, 138-145		
31	Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1235-41	15.4	105
30	Risk stratification of patients with pulmonary embolism based on pulse rate and D-dimer concentration. *Thrombosis and Haemostasis*, **2009**, 102, 683-7	7	29
29	An age-adapted approach for the use of D-dimers in the exclusion of deep venous thrombosis. *American Journal of Hematology*, **2009**, 84, 488-91	7.1	26
28	Challenges and controversies in haemophilia care in adulthood. *Haemophilia*, **2009**, 15 Suppl 1, 20-7	3.3	25
27	Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. *Haemophilia*, **2009**, 15, 853-63	3.3	84
26	Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. *Haemophilia*, **2009**, 15, 952-8	3.3	61
25	Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment. *Haemophilia*, **2009**, 15, 1215-8	3.3	16
24	Cardiovascular disease in patients with hemophilia. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 247-54	15.4	91
23	Safety and sensitivity of two ultrasound strategies in patients with clinically suspected deep venous thrombosis: a prospective management study. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 2035-41	15.4	60
22	Cyproterone acetate- and ethinyloestradiol-containing oral contraceptive as a risk factor for upper extremity deep venous thrombosis-a case report. *European Journal of Contraception and Reproductive Health Care*, **2009**, 14, 160-3	1.8	1
21	Glucose 6-phosphate dehydrogenase deficiency in an elite long-distance runner. *Blood*, **2009**, 113, 2118-9	2.2	5
20	How I treat age-related morbidities in elderly persons with hemophilia. *Blood*, **2009**, 114, 5256-63	2.2	154

19	Out of Hospital Treatment of Acute Pulmonary Embolism in Patients with a Low NT-ProBNP Level.. *Blood*, **2009**, 114, 3996-3996	2.2	
18	Role of Glycoprotein Ib Mobility in Platelet Function.. *Blood*, **2008**, 112, 1850-1850	2.2	
17	Improving the Efficacy of Non-Radiologic Exclusion of Deep Venous Thrombosis in the Elderly Using the Thrombin Generation Assay. *Blood*, **2008**, 112, 3815-3815	2.2	
16	The role of fibrin monomers in optimizing the diagnostic work-up of deep vein thrombosis. *Thrombosis and Haemostasis*, **2007**, 97, 807-813	7	10
15	The role of fibrin monomers in optimizing the diagnostic work-up of deep vein thrombosis. *Thrombosis and Haemostasis*, **2007**, 97, 807-13	7	3
14	Who is at risk for occult cancer after venous thromboembolism?. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2731-3	15.4	4
13	Rituximab-induced serum sickness. *British Journal of Haematology*, **2006**, 135, 147	4.5	20
12	Reduced efficacy of clinical probability score and D-dimer assay in elderly subjects suspected of having deep vein thrombosis. *British Journal of Haematology*, **2005**, 129, 653-7	4.5	41
11	Diagnostic performance of D-dimer is lower in elderly outpatients with suspected deep venous thrombosis: response to Aguilar & del Villar. *British Journal of Haematology*, **2005**, 130, 805-805	4.5	
10	Prevalence and Characteristics of Occult Cancer in Patients with Venous Thromboembolism.. *Blood*, **2005**, 106, 1623-1623	2.2	
9	The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. *Haematologica*, **2005**, 90, 214-9	6.6	32
8	Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. *Translational Research*, **2004**, 144, 100-7		13
7	The usefulness of five D-dimer assays in the exclusion of deep venous thrombosis. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 976-81	15.4	37
6	Combination of a normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to exclude deep venous thrombosis. *Circulation*, **2003**, 107, 593-7	16.7	136
5	Usefulness of a semiquantitative D-dimer test for the exclusion of deep venous thrombosis in outpatients. *American Journal of Medicine*, **2002**, 112, 617-21	2.4	26
4	No Influence of Heparin Plasma and Other (Pre)analytic Variables on D-Dimer Determinations. *Clinical Chemistry*, **2002**, 48, 1611-1613	5.5	13
3	No influence of heparin plasma and other (pre)analytic variables on D-dimer determinations. *Clinical Chemistry*, **2002**, 48, 1611-3	5.5	
2	The Early Course of D-dimer Concentration following Pulmonary Artery Embolisation. *Thrombosis and Haemostasis*, **2001**, 86, 1578-1579	7	12

1 The early course of D-dimer concentration following pulmonary artery embolisation. *Thrombosis and Haemostasis*, **2001**, 86, 1578-9 7 3